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Unfortunately, these trials failed to demonstrate additional kidney or cardiovascular protection.
One of the explanations for the failure of these trials appears to be the large variation in drug response between individual patients. All trials to date tested a drug which was targeted to a large heterogeneous population assuming that every individual will show a similar beneficial respond to the drug. Post hoc analyses from the past clinical trials, however, suggest that individual patients show a marked variation in drug response. This highlights the need to personalize treatment taking proper account of the characteristics and preferences of individual patients.
Transitioning to a personalized therapy approach will have implications for clinical trial designs, drug registration and its use in clinical practice. Successful implementation of personalized medicine thus requires engagement of multiple stakeholders including academic community, pharmaceutical industry, regulatory agencies, health policy makers, physicians and patients. This supplement of Diabetes Obesity and Metabolism provides a summary on the state-of-the-art of personalized medicine in diabetic kidney disease from the views of various stakeholders. appears that all drugs induced changes in other renal or CV risk markers (eg, rise in serum potassium and or rise in sodium retention).
Indeed, post hoc analyses of recent trials showed a large variation in the individual response in the targeted risk marker. For example, in the ALTITUDE trial, a large variation in the albuminuria response to aliskiren was observed (interquartile range −49% to +42%). 9 Patients with a more than 30% reduction in albuminuria were at a 50% lower risk compared to placebo-treated patients in whom albuminuria did The enrichment approach applied in SONAR mimics clinical practice where the response is monitored after drug initiation and in case of lack of response or side effects the dose of the drug is down-titrated or discontinued altogether. The SONAR trial was discontinued earlier due to a lower than anticipated event rate. 7, 11 The impact of the enrichment design element on the event rate remains to be seen. 
